Ginkgo Bioworks

American biotechnology company

DNA NYSE SEC CIK 1830214
Follow Ginkgo Bioworks Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $27.7M −5.7% vs same quarter last year
Net income −$41M +49.2% vs same quarter last year
EPS, diluted −$0.64 +55.9% vs same quarter last year
Operating cash flow −$28.3M +10.3% vs same quarter last year
Revenue by quarter
$43.8M
$38.2M
$39.1M
$29.4M
$63.4M
$19.5M
$20.2M
$27.7M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income8 fiscal years
  • Revenue
  • Net income
−$200M$0$200M$400M$600MFY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$170.2M−$313K
FY24$227M−$547K
FY23$251.5M−$893K
FY22$477.7M−$2.1M
FY21$313.8M−$1.8M
FY20$76.7M−$126.6M
FY19$54.2M−$119.3M
FY18--
MarginsShare of revenue
  • Operating margin
  • Net margin
−600%−400%−200%0%FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearOperating marginNet margin
FY25−185.3%−0.2%
FY24−246.5%−0.2%
FY23−343.8%−0.4%
FY22−462.4%−0.4%
FY21−582.6%−0.6%
FY20−178.8%−165.2%
FY19−132.1%−220.2%
FY18--
Free cash flowOperating cash flow minus capital expenditure
−$400M−$300M−$200M−$100M$0FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$178.7M
FY24−$382.1M
FY23−$336.3M
FY22−$304.5M
FY21−$310.3M
FY20−$193.7M
FY19−$66.9M
FY18-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Ginkgo Bioworks
  • Healthcare median
−300%−200%−100%0%FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearGinkgo BioworksHealthcare median
FY25−0.2%−30.6%
FY24−0.2%−47%
FY23−0.4%−58%
FY22−0.4%−80.4%
FY21−0.6%−71.9%
FY20−165.2%−62.2%
FY19−220.2%−46.3%
FY18-−49.6%